XOMA Corp (XOMA) Stock: Coming Catalysts To Watch


XOMA Corp has been an incredibly interesting stock to follow as of late, and I believe that things are going to get even more interesting. Recently, the company announced the initiation of a Phase 2 study looking into their flagship candidate, XOMA 358. Because of the overwhelmingly positive results we saw from the Phase 1 study, the initiation of Phase 2 led to incredible amounts of investor excitement. While we’ve seen ups and downs since, the overall movement has definitely been positive. Now, there are a couple more catalysts heading in XOMA’s direction that investors will want to keep a close eye on. Today, we’ll talk about what to expect.

XOMA Will Be Giving Two Presentations

Yesterday, XOMA announced that it will be giving two presentations relatively soon. The first presentation will be held at the Jefferies Autumn 2015 Global Healthcare Conference in London on Thursday, November 19th at 3:20 p.m. GMT. The second presentation will be held at the 27th Annual Piper Jaffray Healthcare Conference on Tuesday, December 1st at 10:00 a.m. ET. In my opinion, both of these presentations are likely to prove to be a positive catalyst for the stock moving forward. Here’s why:

  • XOMA 358 – First and foremost, investors are already excited about the initiation of the Phase 2 study of XOMA 358, as we saw during the announcement of the initiation. So, I’d imagine that XOMA will take these opportunities to discuss data with regard to how well the Phase 2 study is going. If it’s moving along as analysts expect, they are going to have positive news to announce which will lead to positive movement in the value of the stock.
  • Financial Data Discussion – XOMA also recently announced that it entered into an asset purchase agreement with Agenus West, LLC. Under the agreement, Agenus will acquire XOMA’s manufacturing facility in Berkeley, California along with related assets in a $75 million sales agreement. This is likely to give XOMA the financial padding that investors were looking for and also prove to help along the lines of positive stock movement.

What We Can Expect To See From XOMA Moving Forward

Moving forward, I’m expecting to see incredibly positive news from XOMA. As mentioned above, the two presentations the company will be offering in the near future open solid opportunities for XOMA to “WOW” investors. By releasing solid data with regard to the Phase 2 clinical trial of XOMA 358 as well as revamping opinions with regard to financial stability, XOMA could really use these opportunities to their advantage, and I think they’ll do just that. Also, beyond the presentations, XOMA seems to be doing the right things all around. First off, XOMA 358 is incredibly positive. Also, with the sales agreement between XOMA and Agenus, financial data is likely to start improving, giving the company the breathing room it needs in that area. All in all, things seem to be going well for the company. Therefore, it’s hard not to maintain a bullish outlook on the stock.

What Do You Think?

Where do you think XOMA is headed and why? Let us know your opinion in the comments below!

Leave a Comment